



Errata to the FDA Briefing Document
Pediatric Subcommittee of the
Oncologic Drugs Advisory Committee Meeting (pedsODAC)

June 28, 2016

Tazemetostat

Presented by Epizyme, Inc.

1. Page 12: 2nd paragraph14% in pediatric patients receiving chemotherapy alone
<needs period> Undifferentiated thoracic sarcomas....
2. Page 13: 2nd paragraph The primary objective of the dose-escalation study ,<replace
study with study> is to determine the maximum tolerated dose (MTD).
Corrected: The primary objective of the dose-escalation study is to determine the
maximum tolerated dose (MTD).
3. Page 14: Issue no. 4, second sentence. “In addition, please comment on combining
safety data across multiple mutation <replace mutation with tumor> types.”
Corrected: “In addition, please comment on combining safety data across multiple tumor
types.”
4. Page 14: Issue no.1 must end with a period not a comma
5. Page 14: Issue no.3 must end with a period